VALBIOTIS
7.6.2019 07:37:06 CEST | Business Wire | Press release
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases, today announced that new preclinical results of TOTUM-63 obtained independently by Leiden University (Netherlands) will be presented at the 2019 scientific sessions of the American Diabetes Association, being held from June 7 to 11 in San Francisco, California. In a murine model of prediabetes, TOTUM-63 reduced inflammation in visceral adipose tissue, one of the pathophysiological mechanisms of metabolic diseases, especially type 2 diabetes. Moreover, this study also confirmed the efficacy of TOTUM-63 on sugar and lipid metabolism in this preclinical model.
"This study from Leiden University is important from a scientific standpoint: it demonstrates a new effect of TOTUM-63, the active substance of lead product candidate VALEDIA ® , on visceral adipose tissue inflammation that enriches the multi-target mode of action of TOTUM-63. On the clinical side, as previously announced, we expect to report the results of the international Phase IIA clinical study of VALEDIA ® before July 31 st ," comments Sébastien PELTIER, CEO of VALBIOTIS.
Anti-inflammatory action on visceral adipose tissue
"Obesity, in both humans and mice, leads to an increase and an activation of macrophages in visceral adipose tissue. These immune cells are involved in maintaining a silent metabolic inflammation, thus reducing the body's ability to use insulin. By reducing this inflammation and increasing insulin sensitivity in adipose tissue, TOTUM-63, the active substance of VALEDIA ® , would contribute to the reduction of the release of lipids into the bloodstream," specifies Dr. Bruno GUIGAS, researcher at Leiden University (Netherlands), the lead investigator of the study.
The discovery of this new effect further enriches the multi-target mode of action of TOTUM-63, which was presented at the European Association for the Study of Diabetes (EASD) congress in 2018. This mode of action would already combine the preservation of the pancreas, the improvement of insulin signaling in the muscle and the adipose tissue, the reduction in hepatic steatosis and an improved composition of the intestinal microbiota.
About TOTUM-63, the active substance of VALEDIA ®
Prediabetes is a growing public health issue worldwide that has been acknowledged by international organizations. Without appropriate management, 70% to 90% of prediabetic subjects will develop type 2 diabetes.
VALEDIA® intend to be the first natural and clinically proven solution specifically designed for prediabetics. VALEDIA® contains the active substance TOTUM-63, a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of type 2 diabetes.
The launch of VALEDIA® is planned for 2021, with a health claim for reducing the risk of type 2 diabetes.
TOTUM-63 has already been proven safe and effective in healthy human volunteers during a Phase I/II clinical study. The results of the first international Phase IIA study are expected before 31 July 2019.
ABOUT VALBIOTIS
VALBIOTIS is a French Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases. Its products are made for major players in the health care sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including La Rochelle University, the CNRS and Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled Valbiotis to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and an American office in Boston (MA).
VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS:
http://valbiotis.com/
Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL
Disclaimer
This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 5 April 2017 (application number I.17-012), as well as in the 2017 annual financial report, filed with AMF on 3 April 2018. This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005627/en/
Contact:
VALBIOTIS CORPORATE COMMUNICATION Carole Rocher / Marc Delaunay +33 5 46 28 62 58 medias@valbiotis.com
FINANCIAL COMMUNICATION ACTIFIN Stéphane Ruiz +33 1 56 88 11 14 sruiz@actifin.fr
MEDIA RELATIONS MADIS PHILEO Guillaume De Chamisso +33 6 85 91 32 56 guillaume.dechamisso@madisphileo.com
UNITED STATES SOLEBURY TROUT Rebecca John / Patrick Till +1 646 378 2935 rjohn@troutgroup.com ptill@troutgroup.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capcom’s Onimusha: Way of the Sword Sells Over 1 Million Units on Launch Day!7.9.2026 15:00:00 CEST | Press release
– Total series sales surpass 10 million units driven by this first new title in 20 years – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Onimusha: Way of the Sword, the latest title in the series, have surpassed 1 million units on the first day of its release. Driven by the performance of this title, cumulative sales of the Onimusha series have now surpassed 10 million units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907554827/en/ Onimusha: Way of the Sword key art Onimusha: Way of the Sword, which marks the first new title in the series in over 20 years, is a swordplay action game featuring protagonist Miyamoto Musashi that is set in Edo-era Kyoto. This title enhances the exhilarating sword-based action of the series with cutting-edge technology while also providing a compelling story and beautiful visual depictions. In addition, through several marketing initiatives prior to launch, such as
A2RL Sets New International Benchmark with Europe’s First Five-Car Autonomous Race7.9.2026 14:16:00 CEST | Press release
UAE team Kinetiz wins A2RL’s first race outside of Abu Dhabi during ACI Racing Weekend hosted on Imola’s iconic Autodromo Internazionale Enzo e Dino FerrariWatch the race HERE. The Abu Dhabi Autonomous Racing League (A2RL) completed the first-ever multi-car autonomous race in Europe at the Imola Circuit in Italy on 5 September 2026, as part of ACI Racing Weekend. Kinetiz (UAE) won the League’s inaugural international race, across 12 laps of one of the most technically demanding circuits in world motorsport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907943650/en/ A2RL Sets New International Benchmark with Europe’s First Five-Car Autonomous Race (Photo: AETOSWire) Organised by ASPIRE, the grand challenges arm of Abu Dhabi’s Advanced Technology Research Council (ATRC), A2RL brings together key players across Abu Dhabi’s autonomous mobility ecosystem, with strategic oversight from the Smart and Autonomous Systems Council
Dubai Chambers to Train 14,000 Private Sector Companies in Agentic AI7.9.2026 12:15:00 CEST | Press release
Dubai Chambers has launched specialised Agentic AI training for more than 14,000 private sector companies, helping businesses build the skills needed to adopt the technology across their operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907193930/en/ H.E. Eng. Sultan bin Saeed Al Mansoori speaking during the launch of the training programme (Photo: AETOSWire) The training forms part of Dubai’s wider programme to transition the private sector towards Agentic AI, launched under the directives of H.H. Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister and Minister of Defence of the UAE, and Chairman of The Executive Council of Dubai. Delivered through the new Dubai Chambers Academy, an integrated e-learning platform, the training provides practical guidance on applying Agentic AI in business. Participants will explore tools and solutions that can improve operations, effici
REPLY: A Face Only A Mother Could Love by Robert Gaudette Wins the Reply AI Film Festival 2026, the International Competition Exploring the Intersection of Cinema and Artificial Intelligence7.9.2026 12:02:00 CEST | Press release
Gabriele Salvatores chaired the international jury that selected the winner from more than 3,000 short films submitted from 76 countries. The awards ceremony took place in Venice on Sunday 6 September, alongside the 83rd Venice International Film Festival of La Biennale. Canadian filmmaker Robert Gaudette, with his short film A Face Only A Mother Could Love, has won the Reply AI Film Festival 2026, the international competition created by Reply to explore new frontiers in cinematic language through the use of artificial intelligence. The award was presented on Sunday 6 September in Venice, during a ceremony organised by Reply and Mastercard at the Match Point Arena, set up at Tennis Club Venezia on the Lido, alongside the 83rd Venice International Film Festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907478421/en/ Canadian filmmaker Robert Gaudette, with his short film A Face Only A Mother Could Love, has won the
From China’s Mountains to the World’s Mountains: KAILAS Deepens Its Global Expansion Strategy7.9.2026 11:58:00 CEST | Press release
In late August 2026, KAILAS FUGA, the trail-running brand of KAILAS, a China-based professional outdoor brand, officially opened its first European store in Chamonix, France. As KAILAS’s first directly operated international store, the new location not only gives the brand a more direct presence in the European market, but also marks a new stage in its global expansion — moving from years of investment in products, events, athletes and international channels toward more localized operations and deeper brand development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260906651659/en/ KAILAS First European Store in Chamonix Founded in 2003, KAILAS is one of the world’s three leading full-category climbing brands. Over more than two decades, the company has built its professional capabilities through product development, professional athletes, events and testing in real mountain environments. From mountaineering, rock climbing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom